

Neeltje Steeghs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8612165/publications.pdf>

Version: 2024-02-01

89
papers

4,279
citations

257450

24
h-index

128289

60
g-index

91
all docs

91
docs citations

91
times ranked

6961
citing authors

#	ARTICLE	IF	CITATIONS
1	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	27.0	918
2	Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> , 2019, 575, 210-216.	27.8	722
3	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	21.4	250
4	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	27.8	221
5	The mutational footprints of cancer therapies. <i>Nature Genetics</i> , 2019, 51, 1732-1740.	21.4	212
6	Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 765-776.	4.7	209
7	A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. <i>Nature Communications</i> , 2020, 11, 728.	12.8	140
8	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	12.8	130
9	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. <i>Journal of Clinical Oncology</i> , 2019, 37, 2507-2507.	1.6	113
10	Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 441-464.	1.9	110
11	Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5738-5746.	7.0	68
12	Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. <i>Clinical Pharmacokinetics</i> , 2017, 56, 987-997.	3.5	63
13	Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1309-1318.	1.9	62
14	Imatinib, sunitinib and pazopanib: From flat fixed dosing towards a pharmacokinetically guided personalized dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 258-273.	2.4	56
15	A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. <i>Acta Oncologica</i> , 2015, 54, 1195-1201.	1.8	53
16	Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. <i>Clinical Pharmacokinetics</i> , 2019, 58, 299-308.	3.5	41
17	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. <i>Nature Communications</i> , 2021, 12, 574.	12.8	39
18	RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics. <i>Cancers</i> , 2020, 12, 1372.	3.7	36

#	ARTICLE	IF	CITATIONS
19	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4001-4001.	1.6	35
20	Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group's Therapeutic Drug Monitoring Protocol for a Prospective Study. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 561-567.	2.0	33
21	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
22	Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with <i>KRAS</i> -mutation-positive colorectal, non-small-cell lung and pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 122, 1166-1174.	6.4	30
23	Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 394-402.	4.7	30
24	Phase I study of lapatinib plus trametinib in patients with <i>KRAS</i> -mutant colorectal, non-small cell lung, and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 917-930.	2.3	29
25	Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3005-3005.	1.6	29
26	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. <i>Oncotarget</i> , 2018, 9, 13870-13883.	1.8	28
27	Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1124-1130.	1.0	26
28	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8-8.	1.6	25
29	Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity – A retrospective multicentre study in a large cohort of GIST patients. <i>European Journal of Cancer</i> , 2017, 86, 318-325.	2.8	23
30	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	4.5	22
31	Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours – Results from daily clinical practice. <i>European Journal of Cancer</i> , 2020, 136, 140-148.	2.8	22
32	Phase I Study of Afatinib and Selumetinib in Patients with <i>KRAS</i> -Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. <i>Oncologist</i> , 2021, 26, 290-e545.	3.7	21
33	Precision Dosing of Targeted Therapies Is Ready for Prime Time. <i>Clinical Cancer Research</i> , 2021, 27, 6644-6652.	7.0	21
34	Neoadjuvant Systemic Treatment of Primary Angiosarcoma. <i>Cancers</i> , 2020, 12, 2251.	3.7	20
35	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1256-1266.	7.0	20
36	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981.	1.6	18

#	ARTICLE	IF	CITATIONS
37	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
38	Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 494-505.	4.7	17
39	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	1.6	17
40	Gastrointestinal Stromal Tumours (GIST) in Young Adult (18â€“40 Years) Patients: A Report from the Dutch GIST Registry. <i>Cancers</i> , 2020, 12, 730.	3.7	15
41	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 1832.	3.7	15
42	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. <i>Sarcoma</i> , 2018, 2018, 1-8.	1.3	14
43	Evaluation of the Khorana, PROTECHT, and 5â€“NP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	3.8	14
44	Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer. <i>ESMO Open</i> , 2020, 5, e000619.	4.5	13
45	Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. <i>Clinical Cancer Research</i> , 2021, 27, 5334-5342.	7.0	13
46	Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2020, 59, 941-948.	3.5	12
47	A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 670862.	3.5	12
48	Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. <i>European Journal of Cancer</i> , 2020, 130, 32-38.	2.8	11
49	Driver mutations occur frequently in metastases of wellâ€“differentiated small intestine neuroendocrine tumours. <i>Histopathology</i> , 2021, 78, 556-566.	2.9	11
50	Exposureâ€“response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	2.6	11
51	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG â€“ANITAâ€“. <i>European Journal of Cancer</i> , 2021, 152, 26-40.	2.8	10
52	Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?. <i>Biomedicines</i> , 2021, 9, 1315.	3.2	10
53	Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management. <i>Seminars in Oncology</i> , 2022, 49, 119-129.	2.2	10
54	Encorafenib, binimetinib and cetuximab combined therapy for patients with <i>BRAFV600E</i> mutant metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 161-173.	2.4	9

#	ARTICLE	IF	CITATIONS
55	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2019, 37, 11023-11023.	1.6	9
56	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. Anticancer Research, 2019, 39, 1309-1316.	1.1	8
57	Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. European Journal of Clinical Pharmacology, 2020, 76, 1075-1082.	1.9	8
58	Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers, 2021, 13, 6281.	3.7	8
59	First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. British Journal of Cancer, 2022, 126, 1010-1017.	6.4	8
60	Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors. Annals of Surgery, 2019, Publish Ahead of Print, e1093-e1098.	4.2	7
61	PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study. BMJ Open, 2020, 10, e039449.	1.9	7
62	Healthy volunteers in first-in-human oncology drug development for small molecules. British Journal of Clinical Pharmacology, 2022, 88, 1773-1784.	2.4	7
63	Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS. Therapeutic Drug Monitoring, 2018, 40, 230-236.	2.0	6
64	Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. Cancer Medicine, 2021, 10, 4781-4789.	2.8	6
65	291â€¦Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. , 2020, , .		6
66	Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib. Pharmaceutical Research, 2022, 39, 669-676.	3.5	6
67	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta Oncologica, 2021, 60, 1557-1564.	1.8	5
68	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 4039-4039.	1.6	5
69	Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors. Supportive Care in Cancer, 2021, , 1.	2.2	5
70	RNA-Sequencing of Tumor-Educated Platelets, A Novel Biomarker for Blood Based Sarcoma Diagnostics.. European Journal of Surgical Oncology, 2020, 46, e7.	1.0	4
71	Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer. Clinical Pharmacology and Therapeutics, 2022, 111, 477-484.	4.7	4
72	Boosting pazopanib exposure by splitting intake moments: A prospective pharmacokinetic study in cancer patients.. Journal of Clinical Oncology, 2019, 37, 3119-3119.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data. <i>Supportive Care in Cancer</i> , 2022, 30, 5137-5146.	2.2	3
74	Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 15-32.	10.9	3
75	Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11518-11518.	1.6	2
76	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	1.0	2
77	Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With <i>ALK</i> -Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence" <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1164-1164.	4.7	2
78	Outcomes of advanced angiosarcoma and hemangioendothelioma on propranolol based regimens from sarcoma medical oncology clinic in North India.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22539-e22539.	1.6	2
79	Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3613-3613.	1.6	2
80	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 5780.	3.7	2
81	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019, 2019, 1-11.	1.3	1
82	Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring program.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3117-3117.	1.6	1
83	Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3598-3598.	1.6	1
84	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 411-416.	0.7	1
85	Abstract LBA038: KonTRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. , 2021, , .		1
86	Type of surgery in rectal gastrointestinal stromal tumour (GIST) does not affect outcome in a large european cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, e28.	1.0	0
87	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11556-11556.	1.6	0
88	Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review. <i>BMJ Open</i> , 2022, 12, e053308.	1.9	0
89	Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 578-578.	1.6	0